Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New nerve block could slash opioid use after heart surgery

NCT ID NCT07259824

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a specific nerve block, called SPSIPB, can reduce pain and the need for strong painkillers after minimally invasive heart surgery. Fifty adults were split into two groups: one got the nerve block plus standard care, the other got standard care alone. Researchers measured total opioid use in the first 24 hours after surgery, along with pain scores and recovery speed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bupivacaine
What this could lead to
If effective, this nerve block could become a standard way to reduce pain and opioid use after minimally invasive heart surgery.
What could go wrong
This is a small, single-center study with only 50 participants. The nerve block may not provide significant benefit over standard care, and there are risks like bleeding or infection from the injection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Jan 2026

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients scheduled for elective minimally invasive cardiac surgery (MICS) * Age between 18 and 75 years * American Society of Anesthesiologists (ASA) physical status II-III * Body mass index (BMI) between 18 and 35 kg/m² * Patients who provide written informed consent for participation Exclusion Criteria: * Known allergy or hypersensitivity to local anesthetics * Coagulopathy or current anticoagulant therapy * Pregnancy or breastfeeding * Impaired consciousness or inability to communicate * Failed or technically inadequate block * Refusal to undergo the block procedure * Cognitive or mental disorders preventing valid pain assessment * Opioid intolerance or contraindication to opioid use * Development of intraoperative or postoperative complications requiring reoperation, prolonged mechanical ventilation, or intensive care * Incomplete postoperative data or patient withdrawal from the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart valvular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ankara Bilkent City Hospital

    Ankara, 06800, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.